Building on Progress, Marking New Milestones: The Present and Future of Immunotherapy in Locally Advanced and Early Lung Cancer
1.00 hr(s) | CME , NCPD , MOC , ABIM
Specialty: Immunotherapies , Lung Cancer
Therapeutic Area(s): Oncology , Immunology
Release Date: June 23, 2021
Expiration Date: June 23, 2021
Location: Live Webcast
The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs and rational combinations are starting to show promising activity as neoadjuvant and adjuvant therapies for patients with resectable stage I-III NSCLC as well. Optimal approaches are still being determined, and many questions and controversies remain, but it is essential for oncologists, thoracic surgeons, and other multidisciplinary specialists to work together to make these therapies available to patients with earlier stages of lung cancer. This PeerView Live web broadcast will provide essential updates on the evolving science supporting the use of ICIs in multimodal treatment of unresectable and resectable stage I-III NSCLC. Multidisciplinary perspectives on how to make the most of immunotherapies and rational combinations in the curative intent settings will be shared as well.